What is Cerebrolysin? The trial evidence

Reviewed 19 sourcesPublished by PepVault

Cerebrolysin is a pig-brain peptide mixture, not one peptide: what the stroke, brain injury and dementia trials measured, and where they fall short.

A smiling silver-haired woman in a light-blue top tying her white walking shoes on her front porch step in the morning
Last reviewed
Sources
19
Questions
9
Compounds
1

The short answer

Cerebrolysin is not one peptide but a mixture of hundreds of small peptides and amino acids from digested pig brain proteins, made by Austria's EVER Pharma and given in trials as a daily IV infusion. It is used for stroke and dementia in parts of Europe and Asia, has no FDA approval, and its trials are mixed: company-run studies found better recovery, the independent Cochrane review found no fewer deaths.

Every number checked at its primary source · · 19 sources · How we research

Evidence: Mixed: randomized human trials in stroke, brain injury and dementia, most supported by the manufacturer; independent Cochrane reviews find no effect on stroke deaths and very low-quality evidence in vascular dementia.

A smiling silver-haired woman in a light-blue top tying her white walking shoes on her front porch step in the morning

What is Cerebrolysin?

Cerebrolysin is made by a controlled digestion of pig brain proteins into a mixture of small peptides and amino acids12. In 2015 a lab at Ghent University in Belgium ran a sample bought online through mass spectrometry and counted 638 different peptides in it. Its main components came from the brain's structural proteins, tubulin, actin and myelin basic protein, and the lab found no fragments of the best-known nerve growth factors, BDNF, NGF, GDNF or CNTF1.

That makes it a different kind of product from the peptides most people track. BPC-157 is one molecule: a fixed chain of 15 amino acids, GEPPPGKPADDAGLV3. Cerebrolysin is closer to a broth, hundreds of fragments in one vial with no single active molecule anyone has named. The Ghent team's own reading was that its reported effects likely come from peptides no one has identified yet1.

It is made by EVER Pharma (EVER Neuro Pharma) of Unterach, Austria. The company sponsored the largest stroke trial5 and funded the CARS rehab trial, and members of its clinical research department are authors on its trials4.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where is Cerebrolysin approved?

The Cochrane review describes it as widely used for acute stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries2, and the Ghent lab calls it an approved medicine in some countries1. It has no FDA approval: a search of Drugs@FDA in November 2026 found no application listed for it6. It is also easy to buy online, which is where the Ghent lab got the sample it tested1.

What did the stroke trials find?

The largest trial, CASTA, enrolled 1,070 people in Asia within 12 hours of an ischemic stroke. About half received 30 mL of Cerebrolysin as a daily IV infusion for 10 days and half a saline infusion, both on top of aspirin7. At 90 days its main combined measure of disability, daily function and stroke severity showed no significant difference between the groups7. Among the most severe strokes, a trend favored Cerebrolysin, with 10.5% deaths by day 90 against 20.2% on placebo. That was a post hoc analysis, and the authors asked for a new trial to confirm it7.

CARS tested recovery during rehab instead. Its 208 patients received 30 mL a day by IV infusion for 21 days, starting 24 to 72 hours after the stroke, alongside a 21-day rehabilitation program. On day 90, arm function on the Action Research Arm Test was clearly better than on placebo, and fewer than 5% stopped early4. The authors called the trial exploratory and relatively small4. Pooled with its twin, CARS-2, the 442 patients still showed better arm function at day 908.

The same group of trialists then combined nine randomized trials of 1,879 patients. Neurological scores at day 21 or 30 were better with Cerebrolysin, with roughly one extra patient reaching a clinically relevant improvement for every eight treated9.

The Cochrane review asked a different question. Its authors, whose conflict statements list no ties to the maker, pooled seven trials of 1,773 people, one of them testing Cortexin, a similar extract from cattle brain, and looked at death, dependence and harm2. Deaths showed little to no difference (risk ratio 0.96, moderate-certainty evidence), no trial reported death or dependence at the end of follow-up, and more people had non-fatal serious adverse events on Cerebrolysin (risk ratio 2.39, from three trials of 1,335 people)2. The manufacturer supported three of the multicenter trials2.

Two other reports point the other way. A 2021 safety meta-analysis of 12 trials and 2,202 patients, led by a researcher who also worked on the CAPTAIN brain-injury trials, found no significant difference in harms against placebo1012. And in a 2025 single-center study, 68% of 50 patients given Cerebrolysin after a clot was pulled out with a device were independent at 90 days, against 44% of 50 earlier patients matched to them. It was open-label, with past patients instead of a placebo group, and the authors call for randomized trials11.

Does it help after a brain injury?

The CAPTAIN trials gave Cerebrolysin after moderate to severe traumatic brain injury, on top of standard care1213. CAPTAIN I, an Asian-Pacific trial of 46 patients, just missed significance on its main measure across all patients and reached it only among those who completed the protocol12. CAPTAIN II, a single-center trial of 142, found a small-to-medium benefit at day 9013. Pooled, the 185 patients showed a small-to-medium effect at days 30 and 9014.

Two things limit how far these go. The trials were small, and each scored success on an ensemble of 13 or 14 outcome scales rather than on one hard outcome such as death or return to work1213. And the three reports share most of their authors121314.

The brain-injury work has an animal side too. In rats with a mild closed head injury, daily Cerebrolysin for 10 days improved long-term function, best at 2.5 mL per kg; the study had co-authors from EVER Pharma15. Results in rats often don't carry over to people.

What about dementia?

For vascular dementia, the Cochrane review found six randomized trials of 597 people, and the three that reported their funding were all supported by industry16. Courses of IV Cerebrolysin improved cognition and global function, but the evidence was rated very low quality, the trials carried a high risk of bias, and the authors wrote that any benefit may be too small to be clinically meaningful16. No new trial appeared between the 2013 review and its 2019 update16.

In Alzheimer's disease, a 2002 trial gave 192 people 30 mL by IV five days a week for four weeks. At week 12, 76% on Cerebrolysin were rated unchanged or better on the clinicians' global scale, against 57% on placebo, though the groups differed at the start in age and in how many had hallucinations17. A 2015 meta-analysis of six trials found better cognition at 4 weeks that was no longer significant at 6 months, while the global rating stayed better at 6 months18. Its authors include the biostatistician of the CARS stroke trial and a member of the company's clinical research department418.

A subgroup analysis of a dose-finding trial, covering 133 people with moderate to moderately severe Alzheimer's (about 33 per group), found better global function at week 24 with all three doses, while the mental-status exam (MMSE) and total daily-living scores showed no significant treatment effect19.

How was it given in the trials?

TrialConditionWhat the trial gave
CASTA7Acute ischemic stroke30 mL IV infusion daily for 10 days
CARS4Stroke, early rehab30 mL IV infusion once daily for 21 days
CAPTAIN I and II1213Moderate to severe brain injury50 mL a day for 10 days, then two 10-day cycles of 10 mL a day
Panisset 200217Alzheimer's disease30 mL IV, five days a week for four weeks
Alvarez 201119Alzheimer's disease10, 30 or 60 mL in a 100 mL IV infusion, 5 days a week for 4 weeks, then 2 days a week for 8 weeks

These are the amounts the trials gave, under medical supervision, not a protocol to copy. Courses run at home, including injections into muscle, are outside what these trials tested.

What side effects were seen?

In most trials side effects were about as common as on placebo491318. In the 2002 Alzheimer's trial, 64% on Cerebrolysin and 73% on placebo had any adverse event, most often headache, dizziness, weight loss and anxiety17.

The Cochrane stroke review is the result worth knowing. The total number of people with serious events was about even, but non-fatal serious events were more common with Cerebrolysin (risk ratio 2.39), most of all on the 30 mL a day for 10 days schedule (2.87)2. The safety analysis linked to the trial network found no significant difference10.

What do people who run it report?

Commonly reported: clearer, quicker thinking and easier word-finding during or after a course, a lift in mood for some, and, on the other side, discomfort from the large injection volumes and a warm flush, dizziness or a headache around the injection. Most people run it as a 10 to 20 day course and repeat it after a break of a few months.

These are user reports, not trial results. The trials measured recovery scores in hospital patients after a stroke or head injury, or in people with dementia, not how healthy people feel.

How should you read a Cerebrolysin claim?

  • Which outcome? Rehab and combined scores improved in several company-run trials. Deaths did not change in the independent stroke review.
  • Who ran it? Most positive trials and pooled analyses come from the maker and one network of trialists; the Cochrane reviews are the independent read.
  • Which product? The trials used the maker's product, given in hospital. A vial bought online has no such record behind it, and even the genuine product is a mixture with no single active molecule named.
  • Which species? The animal work explains why the trials were run, not what a course does in a person.

None of this means Cerebrolysin does nothing. It has a real body of randomized human trials, and some of them show recovery signals. It means the hard outcomes, death and dependence, have not moved in the independent reviews, and the strongest results still wait for a large trial run by someone other than the maker.

Track it in the app

Sources

  1. Gevaert B, et al. Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Test Anal. 2015. PubMed 26017115
  2. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023. PubMed 37818733
  3. Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012. PubMed 22300085
  4. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. PubMed 26564102
  5. ClinicalTrials.gov. NCT00868283: The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke (CASTA). Sponsor: Ever Neuro Pharma GmbH. clinicaltrials.gov
  6. U.S. Food and Drug Administration. Drugs@FDA (openFDA drugsfda endpoint), search for cerebrolysin, November 2026: no matches. api.fda.gov
  7. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012. PubMed 22282884
  8. Guekht A, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017. PubMed 28707130
  9. Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018. PubMed 29248999
  10. Strilciuc S, et al. Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials. Pharmaceuticals (Basel). 2021. PubMed 34959697
  11. Staszewski J, et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation. Transl Stroke Res. 2025. PubMed 40325343
  12. Poon W, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I, a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020. PubMed 31494820
  13. Muresanu DF, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020. PubMed 31897941
  14. Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021. PubMed 33620612
  15. Zhang Y, et al. Prospective, randomized, blinded, and placebo-controlled study of Cerebrolysin dose-response effects on long-term functional outcomes in a rat model of mild traumatic brain injury. J Neurosurg. 2018. PubMed 29303438
  16. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019. PubMed 31710397
  17. Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm (Vienna). 2002. PubMed 12111446
  18. Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015. PubMed 25832905
  19. Alvarez XA, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2011. PubMed 20500802

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo